Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +43.91%
#3 Pons Pons +21.40%
#4 ADO Protocol ADO Protocol +18.01%
#5 Main Street Yield Main Street Yield +17.48%
#6 Collect on Fanable Collect on Fanable +16.09%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.52%
#8 o1.exchange o1.exchange +13.32%
#9 Velvet Velvet +12.38%
#10 Ontology Gas Ontology Gas +12.35%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Classement en actions #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Prix de l'action
$9.60
Dernière synchronisation: 2025-05-21
Capitalisation boursière
$1.08B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange OptiNose, Inc. (OPTN)

Catégorie

Healthcare
Ratio P/S pour OptiNose, Inc. (OPTN)
Ratio P/S au August 2026 TTM : 1.24
Selon les derniers rapports financiers et le cours de l'action de OptiNose, Inc., le ratio cours/ventes actuel (TTM) est 1.24. À la fin de 2023, le ratio P/S était de 30.55.
Historique du ratio P/S pour OptiNose, Inc. de 2015 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 1.24 42.85%
2024 0.87 -97.16%
2023 30.55 1,366.42%
2022 2.08 -88.74%
2021 18.51 -69.68%
2020 61.04 -63.50%
2019 167.24 -68.05%
2018 523.46 0.00%
2017 0.00 -100.00%
2016 16.31 -99.98%
2015 89.58K 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
7.73 521.93%
IN